Mikhail Blagosklonny Takes Oncotarget to Prominence and Success

DATE: September 17, 2017

AUTHOR: admin

About Oncotarget

Established in 2010, Oncotarget is a weekly peer-reviewed journal covering research on all aspects of oncology. Mikhail Blagosklonny, the editor-in-chief of Oncotarget, is a scientist who specializes in cancer and aging studies. He formerly worked at Roswell Park Cancer Institute as a professor of oncology.

Mikhail Blagosklonny went to the First Pavlov State Medical University of St. Petersburg where he earned both his Ph.D. in Experimental Medicine and Cardiology and M.D. in Internal Medicine. In 2002, New York Medical College appointed Blagosklonny as associate professor of medicine before leaving for Ordway Research Institute as a senior scientist. He held the position until 2009 when he joined Roswell Park Cancer Institute as professor of oncology. Driven by a passion for developing cancer therapies, Mikhail Blagosklonny wants to protect norm cells from damage while maintaining the underlying mechanisms of aging and anti-aging drugs and more information click here.

Mikhail Blagosklonny has recently formulated a hypothesis about the possible use of rapamycin, a popular cancer drug and role of TOR signaling in aging as a possible treatment for life extension. The longevity research field considers Mikhail as the most passionate advocates for rapamycin. Besides being the editor-in-chief of Oncotarget, Aging and Cell Cycle, Mikhail Blagosklonny is associate editor of Cancer Biology & Therapy. He also serves on the board of Cell Death & Differentiation.

Editors at Oncotarget led by Mikhail Blagosklonny evaluate manuscripts on merit, quality data, and scientific novelty regardless of author’s religious belief, race, citizenship, and sexual orientation. The decision to publish the content on Oncotarget is not based on political forces. Interestingly, the editorial staff keeps information about the manuscript confidential. In fact, editors can’t use unpublished information for other purposes. Again, editors partners with other authors to assess documents without conflicts of interest stemming from the competitors. Each of Oncotarget’s issue can be printed on special demand. Oncotarget’s mission is to make scientific research widely and quickly accessible. That helps maximize the impact of research and allow quick sharing of discoveries. Oncotarget looks forward to linking up different fields of biomedical sciences in a bid to eliminate borders between specialists and resume it.


Copyright 2018. NsThemes WordPress Theme.